Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
NCT00671788Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Jun 2008
- Primary completion
- Dec 2010
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in ovarian carcinoma, fallopian tube carcinoma (PFTC) and primary peritoneal carcinoma (PPC), sponsored by GOG Foundation. Primary endpoints: Progression-free Survival at 6 Months and Objective Tumor Response. Started Jun 2008; status: completed.
02
Drugs
dasatinib
03
Conditions
ovarian carcinomafallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00671788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00671788.